BAKER BROS ADVISORS LP's Q4 2021 13F: 5 new positions, 5 exits
Form 13F-HR for the quarter ended Dec 31, 2021 · filed Feb 14, 2022 · 116 reported positions · accession 0001104659-22-022725
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Increased | Incyte Corporation (INCY) | 9.8% | 12.1% | +2.3 pts | +1.6M sh | +5% |
| New | Entrada Therapeutics, Inc. (TRDA) | — | 0.4% | +0.4 pts | +4.7M sh | new |
| Reduced | Seagen Inc. (SGEN) | 35.6% | 35.5% | 0.0 pts | −395K sh | −1% |
| Increased | ChemoCentryx, Inc. (CCXI) | 0.0% | 0.3% | +0.3 pts | +1.33M sh | +442% |
| New | 2seventy bio, Inc. (TSVT) | — | 0.1% | +0.1 pts | +833K sh | new |
| Reduced | Fulgent Genetics, Inc. (FLGT) | 0.2% | 0.1% | −0.1 pts | −200K sh | −50% |
| Increased | Travere Therapeutics, Inc. (TVTX) | 0.2% | 0.4% | +0.2 pts | +629K sh | +31% |
| Increased | Krystal Biotech, Inc. (KRYS) | 0.1% | 0.3% | +0.1 pts | +200K sh | +33% |
| Increased | Affimed N.V. (AFMD) | 0.0% | 0.1% | +0.1 pts | +2.49M sh | +1512% |
| Increased | Replimune Group, Inc. (REPL) | 0.0% | 0.1% | +0.1 pts | +440K sh | +287% |
| Exited | Mirum Pharmaceuticals, Inc. (MIRM) | 0.1% | — | −0.1 pts | −647K sh | −100% |
| New | Sarepta Therapeutics, Inc. (SRPT) | — | 0.1% | +0.1 pts | +123K sh | new |
| Exited | Aurinia Pharmaceuticals Inc. (AUPH) | 0.1% | — | −0.1 pts | −521K sh | −100% |
| Reduced | Novavax, Inc. (NVAX) | 0.1% | 0.0% | −0.1 pts | −60,588 sh | −56% |
| New | FibroGen, Inc. (FGEN) | — | 0.0% | 0.0 pts | +580K sh | new |
| Reduced | Albireo Pharma, Inc. (ALBO) | 0.1% | 0.0% | 0.0 pts | −308K sh | −75% |
| Increased | Chinook Therapeutics, Inc. (KDNY) | 0.1% | 0.2% | +0.1 pts | +431K sh | +23% |
| Increased | Relmada Therapeutics, Inc. (RLMD) | 0.0% | 0.1% | 0.0 pts | +294K sh | +146% |
| Increased | Alkermes plc (ALKS) | 0.2% | 0.2% | 0.0 pts | +272K sh | +22% |
| Increased | Legend Biotech Corporation (LEGN) | 0.5% | 0.6% | 0.0 pts | +125K sh | +5% |
| Exited | Amryt Pharma plc (AMYT) | 0.0% | — | 0.0 pts | −518K sh | −100% |
| Exited | Acceleron Pharma Inc. (XLRN) | 0.0% | — | 0.0 pts | −22,430 sh | −100% |
| Increased | Global Blood Therapeutics, Inc. (GBT) | 0.4% | 0.5% | +0.1 pts | +97,324 sh | +3% |
| Increased | Axsome Therapeutics, Inc. (AXSM) | 0.1% | 0.1% | 0.0 pts | +71,913 sh | +13% |
| Increased | TCR2 Therapeutics Inc. (TCRR) | 0.0% | 0.0% | 0.0 pts | +577K sh | +327% |
| Reduced | Crinetics Pharmaceuticals, Inc. (CRNX) | 0.1% | 0.1% | 0.0 pts | −93,176 sh | −10% |
| Increased | Tricida, Inc. (TCDAQ) | 0.0% | 0.1% | 0.0 pts | +248K sh | +24% |
| Reduced | Amarin Corporation plc (AMRN) | 0.5% | 0.3% | −0.1 pts | −686K sh | −3% |
| Increased | Aerovate Therapeutics, Inc. (AVTE) | 0.2% | 0.1% | 0.0 pts | +180K sh | +11% |
| Reduced | Opthea Limited (CYVNY) | 0.1% | 0.1% | 0.0 pts | −187K sh | −6% |
| New | Foghorn Therapeutics Inc. (FHTX) | — | 0.0% | 0.0 pts | +45,027 sh | new |
| Exited | Mereo BioPharma Group plc (MREO) | 0.0% | — | 0.0 pts | −293K sh | −100% |
| Increased | Otonomy, Inc. (OTIC) | 0.1% | 0.1% | 0.0 pts | +151K sh | +2% |
| Increased | Talis Biomedical Corporation (TLIS) | 0.2% | 0.1% | −0.1 pts | +50,000 sh | +1% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 84.1% of the equity book
Changes in the top 10 this quarter: MRTX entered · BCRX entered · PRLD left · NVTA left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Seagen Inc. (SGEN) | 35.6% | 35.5% | |
| 2 | BeiGene, Ltd. (ONC) | 18.8% | 15.5% | |
| 3 | Incyte Corporation (INCY) | 9.8% | 12.1% | |
| 4 | Kodiak Sciences Inc. (KOD) | 6.2% | 6.1% | |
| 5 | ACADIA Pharmaceuticals Inc. (ACAD) | 3.1% | 4.8% | |
| 6 | BioMarin Pharmaceutical Inc. (BMRN) | 2.6% | 3.3% | |
| 7 | Ascendis Pharma A/S (ASND) | 3.2% | 3.0% | |
| 8 | argenx SE (ARGX) | 1.5% | 1.9% | |
| 9 | Mirati Therapeutics, Inc. (MRTX) | 1.1% | 1.0% | Entered the top 10 |
| 10 | BioCryst Pharmaceuticals, Inc. (BCRX) | 0.8% | 0.9% | Entered the top 10 |
| — | Prelude Therapeutics Inc. (PRLD) | 1.4% | 0.6% | Left the top 10 |
| — | Invitae Corporation (NVTA) | 1.2% | 0.7% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).